NUVISAN & ICB generating value to your pharma projects

with Dr. Dietrich Bruchmann & Dr. Hans Lindner

The increasing complexity in the early development phase led to a booming demand for sophisticated CRO/CDMO partners. In order to seize these emerging opportunities, NUVISAN has been fastly developing its capabilities and capacities since 2010 through different acquisitions and partnerships in Europe. In July 2020, NUVISAN acquired large parts of Bayer's Berlin-based small molecule research unit to expand its portfolio of services. Learn more about our services.